Astellas Pharma Inc (Astellas) has acquired Universal Cells Inc for $102.5m.

The acquirer company is a pharmaceutical company based in the US, while the acquired company, also based in the US, is a biotech company.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The acquisition will enable Astellas Pharma to use Universal Cells’ proprietary Universal Donor Cell technology to manufacture cell therapy products in a number of therapeutic areas.

Shenzhen Neptunus Bioengineering has agreed to acquire a 60% share in a medical tech company based in Tianjin for CNY48.6m ($7.69m).

The Chinese pharmaceutical company will complete the transaction through its Ningbo-based trade unit.

“Shenzhen Neptunus Bioengineering has agreed to acquire a 60% share in a medical tech company based in Tianjin for CNY48.6m ($7.69m).”

Mallinckrodt Pharmaceuticals has completed the acquisition of Sucampo Pharmaceuticals for $1.2bn.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The acquisition was announced in December 2017 and will add Sucampo’s AMITIZA (lubiprostone), RESCULA, VTS-270 and CPP-1X / sulindac products to Mallinckrodt’s portfolio.

Deutsche Bank was appointed as the financial advisor for the transaction by Mallinckrodt, and Wachtell, Lipton, Rosen & Katz as the legal advisor.

Jefferies served as the exclusive financial advisor for Sucampo and Cooley served as the legal advisor for the transaction.